News

Morgan Stanley upgraded Grindr’s stock to Overweight from Equal‑weight, setting a $18 price target. The brokerage cites the company’s ultra‑premium subscription tier EDGE, an AI‑powered offering, projected to bring $78 million in revenue by 2028, and its telehealth brand Woodwork, expected to generate $28 million in the same year. Together these in...

Full article

Progress Software (NASDAQ: PRGS) reported Q2 2026 results that exceeded consensus expectations, with adjusted earnings per share of $1.62 and revenue of $253.47 million, a 4.87 % increase over the Zacks Consensus Estimate. The company cited AI‑powered product demand as a key driver of revenue growth and operating margin, which stood at 40 %. CEO Yo...

Full article

The conference call will be followed by an online replay available on the Company's website approximately two hours after the conclusion of the call, remaining accessible for 12 months. FB Financial Corporation operates through its wholly owned banking subsidiary, FirstBank, with 90 full‑service branches across Tennessee, Kentucky, Alabama, and Geo...

Full article

FB Financial Corporation (NYSE: FBK) will release its 2026 second quarter results of operations on July 13, 2026, after the close of market trading. The Company will host a conference call on July 14, 2026, at 8:00 a.m. Central Time to discuss its quarterly results. Investors and analysts can participate by dialing 877-883-0383 with confirmation co...

Full article

Furthermore, tangible book value per share (TBVPS) growth has been mediocre at 8.8% annual clip over the last two years, suggesting limited asset expansion. While the stock's valuation is fair at 1.3× forward P/B, the upside appears limited compared to potential downside risks. As a result, investors may want to consider alternative stocks with mor...

Full article

FB Financial's stock performance has been lackluster, posting a small loss of 1.4% since January 2026 and falling short of the S&P 500's 8.5% gain during that period, currently trading around $55.36. The company's revenue growth has disappointed, with a compounded annual growth rate of 1.4% over the last five years, below market standards. Addition...

Full article

Beyond AML, the company is advancing SLS009, a CDK9 inhibitor, which has shown early efficacy signals. The combination of a promising clinical portfolio, significant cash reserves, and impending trial readouts positions SLS as an undervalued oncology opportunity with substantial upside potential for shareholders.

Full article

On June 23, SLS shares traded at $9.07, and analysts highlighted a bullish thesis that the REGAL study’s final unblinding—expected after the last two events—could remove primary uncertainty and support a regulatory submission by late 2026. A valuation model projects a post‑data target price of $16.50, implying approximately 129.8% upside from the t...

Full article

Sellas Life Sciences Group Inc. (NASDAQ:SLS) saw its share price rise 14.83% to $10.53 per share on Thursday after a regulatory filing disclosed amendments to employment and severance agreements for President and CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic. The changes create lump‑sum payments upon a “change of control,” fueling spec...

Full article

The company aims to reach production by the end of 2027, marking a significant transition from an exploration company to a resource and operational company with guaranteed cash flow. Stalker's comments highlight BHL's growth strategy and project development plans, positioning the company for future success in the lithium market.

Full article